Nootropic Peptides Overview: Semax, Selank, Cerebrolysin, and Dihexa Explained

What Are Nootropic Peptides?

Nootropic peptides are endogenous or synthetic short-chain amino-acid sequences that cross or act upstream of the blood-brain barrier to modify neurotransmitter release, growth-factor expression, or synaptic plasticity. They differ from classic stimulants such as amphetamines or modafinil in that they aim to support the brain's own repair and signaling pathways rather than forcing acute catecholamine release.

The term "nootropic" was coined by Romanian chemist Corneliu Giurgea in 1972, and his original definition required that a compound enhance learning without significant toxicity or sedation. Peptides fitting this profile have been developed primarily in Soviet-era and post-Soviet research programs, which explains why agents like Semax and Selank were registered as drugs in Russia and Ukraine decades before Western clinical trials began.

From a mechanistic standpoint, four pathways dominate this class. First, brain-derived neurotrophic factor (BDNF) signaling governs synaptic long-term potentiation and neuronal survival. Second, GABA-A and GABA-B modulation controls anxiolytic tone without sedation. Third, nerve growth factor (NGF) and related neurotrophins support cholinergic neurons implicated in working memory. Fourth, hepatocyte growth factor receptor (c-Met) agonism may drive dendritic branching at concentrations orders of magnitude below traditional neurotrophins. Each of the four agents reviewed below maps onto at least one of these pathways [1].

Semax: BDNF Upregulation and Dopaminergic Focus

Semax (ACTH 4, 7 Pro-Gly-Pro) is a synthetic heptapeptide derived from the adrenocorticotropic hormone fragment 4, 10. It does not stimulate cortisol secretion at typical doses. Instead, it upregulates BDNF and nerve growth factor mRNA in the rat hippocampus within two hours of intranasal administration, an effect demonstrated by Dolotov et al. (2006) in a controlled rodent study published in the Journal of Neurochemistry [2].

In human research, Semax has been registered in Russia since 1994 for stroke rehabilitation and optic nerve disease. A controlled clinical study of 60 ischemic stroke patients found that 0.1% Semax nasal drops (roughly 300 mcg per dose) administered twice daily for 10 days significantly improved neurological deficit scores compared to standard care alone (P<0.05) [3]. That is a patient population with acute brain injury, not healthy adults seeking cognitive optimization, and the distinction matters clinically.

Mechanistically, Semax also modulates the dopaminergic and serotonergic systems in the prefrontal cortex, which may explain user-reported improvements in attention and working memory. A rodent study in Bulletin of Experimental Biology and Medicine found that Semax increased dopamine and serotonin metabolite ratios in the prefrontal cortex after seven days of intranasal dosing [4].

Typical dosing in clinical and compounding contexts ranges from 300 to 600 mcg intranasally, once or twice daily, for cycles of two to four weeks. Side effects reported in the Russian literature include mild nasal irritation and transient headache. No serious adverse events have been recorded at doses below 1 to 000 mcg/day in the published human data, though long-term safety in healthy adults remains unstudied in controlled trials.

Selank: Anxiolytic Action Without Benzodiazepine Dependence

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the endogenous immunomodulatory peptide tuftsin. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and registered in Russia as an anxiolytic in 2009.

Its primary anxiolytic mechanism involves enhancement of GABAergic tone. A study by Semenova et al. (2010) published in the Bulletin of Experimental Biology and Medicine demonstrated that Selank at 300 mcg/kg intraperitoneally produced anxiolytic effects in rats comparable to diazepam 1 mg/kg, without the motor impairment or dependence liability seen with benzodiazepines [5]. Selank also modulates the expression of genes encoding GABA-A receptor subunits, which distinguishes it from drugs that merely bind the receptor allosterically.

Beyond anxiety, Selank appears to stabilize enkephalin degradation by inhibiting enkephalinase enzymes, prolonging the activity of endogenous opioid peptides in a localized, low-magnitude way. This second mechanism may contribute to mood stabilization observed in clinical reports.

In a double-blind trial of 62 patients with generalized anxiety disorder conducted at the Serbsky National Medical Research Centre in Moscow, Selank 400 mcg intranasally twice daily for 14 days reduced Hamilton Anxiety Rating Scale scores by 48% versus 22% for placebo (P<0.01) [6]. Tolerability was described as good, with no clinically significant changes in blood pressure, heart rate, or liver enzymes.

Typical compounding doses in the United States range from 250 to 500 mcg intranasally once or twice daily. Selank appears well-suited for users experiencing cognitive dysfunction driven by elevated anxiety, because it may address the anxiety component without blunting alertness.

Cerebrolysin: Neuropeptide Mixture With Stroke and Dementia Trial Data

Cerebrolysin is not a single peptide. It is a standardized enzymatic hydrolysate of porcine brain proteins, containing approximately 25% low-molecular-weight peptides (molecular weight <10 kDa) and 75% free amino acids. The active peptide fraction mimics the physiological activity of NGF and BDNF without the molecular size that prevents those full proteins from crossing the blood-brain barrier. It is manufactured by EVER Pharma (Austria) and is approved or registered in more than 30 countries, though not by the FDA for any indication.

The evidence base for Cerebrolysin is the deepest among the four agents reviewed here. The CASTA trial (N=1,070), a multicenter randomized controlled trial published in Stroke (2012), found that Cerebrolysin 30 mL IV daily for 10 days did not significantly improve the primary endpoint of favorable functional outcome (modified Rankin Scale score 0, 1) at 90 days versus placebo in acute ischemic stroke patients (P=0.23) [7]. That null result for a hard stroke outcome is important context. The drug is not a stroke cure.

Where the data look more promising is in vascular dementia and Alzheimer's disease. A Cochrane systematic review by Chen et al. (2013) covering six RCTs (N=597) found that Cerebrolysin produced statistically significant improvements on the Clinical Global Impression scale and the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) compared to placebo, though the authors rated evidence quality as moderate due to heterogeneity [8]. A more recent RCT published in the Journal of Alzheimer's Disease (2020, N=316) found that Cerebrolysin 30 mL IV over 20 sessions significantly slowed decline on the Neuropsychiatric Inventory at 24 weeks (P<0.01) [9].

Dosing in clinical settings typically runs 5 to 10 mL IM or 10 to 30 mL IV, administered in courses of 10 to 20 daily injections. The IV route requires medical supervision. Known side effects include transient dizziness, nausea, and, rarely, agitation. The porcine-derived source material means Cerebrolysin is contraindicated in patients with known pork allergies.

Dihexa: The Highest-Potency Cognitive Peptide in Preclinical Research

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed at Washington State University in the laboratory of Joseph W. Harding, PhD, as a stable, orally bioavailable angiotensin IV analog. It acts as a potent agonist at the HGF/c-Met signaling complex, which drives hippocampal synaptogenesis and dendritic spine formation.

The pharmacological potency claims are extraordinary and deserve careful framing. Harding's group reported that Dihexa is approximately seven orders of magnitude more potent than BDNF itself in a spatial memory task (Morris water maze) in aged rats [10]. That figure comes from a single laboratory's rodent data published in the Journal of Pharmacology and Experimental Therapeutics (2013) and has not been replicated in independent human RCTs. No Phase II or Phase III human trials have been published as of early 2025.

A practical decision framework for clinicians considering Dihexa: (1) Confirm the patient has exhausted or declined approved pharmacological options. (2) Document baseline cognitive testing, such as the Montreal Cognitive Assessment (MoCA), before starting. (3) Start at 10 mg orally or transdermally and reassess at four weeks using the same standardized tool. (4) Discontinue if no objective improvement appears at eight weeks, because the absence of human RCT data makes extended empirical trials difficult to justify. (5) Disclose the research-only status in writing before initiating any protocol.

Oral bioavailability is estimated at roughly 80% in rodent models, and the peptide appears resistant to peptidase degradation due to its synthetic side chains. Reported doses in clinical and biohacker communities range from 10 to 30 mg daily. Transdermal formulations are also used, with no comparative bioavailability data in humans published to date. The side-effect profile is essentially unknown beyond rodent toxicology, where no significant organ toxicity was observed at doses up to 10 mg/kg.

Comparing the Four Agents: Mechanisms, Evidence Strength, and Clinical Fit

The four peptides target different patient profiles. Semax suits patients with attentional deficits, post-acute-COVID cognitive symptoms, or stroke rehabilitation goals, given its BDNF-upregulating and dopaminergic mechanisms. Selank fits best for anxiety-driven cognitive impairment, where GABAergic support can reduce the attentional cost of chronic stress without sedation. Cerebrolysin has the broadest clinical trial base and is most appropriate for patients with diagnosed vascular dementia or moderate Alzheimer's disease, under physician supervision with IV access. Dihexa is the most experimental and should be reserved for patients enrolled in structured clinical monitoring or formal research protocols.

Evidence hierarchy across the four agents breaks down this way. Cerebrolysin has Phase III RCT data with a Cochrane review. Semax and Selank have Phase II-equivalent controlled trials from Russian regulatory programs, with published data in indexed journals. Dihexa has only preclinical data. None has FDA approval for a cognitive indication.

Stacking these agents is common in the biohacking community, but published data on combination protocols are absent. Clinicians should evaluate each agent independently before combining them, starting with the one best matched to the dominant symptom.

Regulatory Status, Compounding, and Prescribing in the United States

None of the four peptides carries FDA approval for cognitive enhancement or any neurological indication in the United States. Cerebrolysin is a foreign-approved prescription drug that may be imported for personal use under FDA personal importation policy, subject to quantity limits. Semax and Selank have historically been available through FDA-registered 503A compounding pharmacies as research compounds, though availability fluctuates with FDA enforcement priorities.

The FDA's 2023 and 2024 actions on peptide compounding expanded the list of bulk substances under scrutiny. Clinicians and patients should verify current compounding availability before initiating a protocol. The FDA's bulk substance nomination database at accessdata.fda.gov provides the most current status [11].

Prescribing physicians bear responsibility for informed consent that covers three points: the absence of FDA approval, the limited long-term safety data in healthy humans, and the fact that cognitive benefits observed in disease populations may not translate to healthy adults. The American Academy of Anti-Aging Medicine and several functional medicine bodies have published position statements recommending documented informed consent for off-label peptide prescribing, though no major U.S. specialty society has issued formal clinical guidelines on nootropic peptide use specifically [12].

Safety Monitoring for Patients on Nootropic Peptide Protocols

Baseline and follow-up laboratory work should be standard practice. A reasonable monitoring panel includes a complete metabolic panel, complete blood count, and fasting lipids at baseline and at three months. Liver enzyme elevation has not been a noted signal for Semax, Selank, or Dihexa in available data, but Cerebrolysin courses require baseline renal function assessment because the drug is renally cleared and dose adjustment is standard in patients with creatinine clearance <30 mL/min.

Neuropsychological monitoring matters as much as laboratory work. The MoCA (30-point scale) takes roughly 10 minutes to administer, is freely available at mocatest.org, and provides a reproducible cognitive baseline. Clinicians should document MoCA scores at baseline, at four weeks, and at the end of any treatment course. A change of 2 or more points on the MoCA is generally considered clinically meaningful, per the original validation by Nasreddine et al. (2005) in the Journal of the American Geriatrics Society [13].

Patients should be counseled to report any new onset of headache persisting beyond 48 hours, mood disturbances, or sleep disruption, because all four peptides interact with neurotransmitter systems in ways that could destabilize baseline mood in susceptible individuals. Patients with a personal or family history of bipolar disorder or psychosis should not initiate these agents without psychiatric co-management.

What Patients Should Ask Their Prescriber Before Starting

Before starting any nootropic peptide, a patient should confirm the prescriber can answer four questions directly. Is the peptide coming from an FDA-registered compounding pharmacy with a certificate of analysis? Has baseline cognitive testing been documented? What is the stopping criterion if there is no measurable improvement? And what is the monitoring plan for adverse effects?

The absence of a clear answer to any of these four questions is a reason to pause. Peptide therapy for cognitive health is a legitimate area of clinical investigation, but the absence of Phase III human trial data for three of the four agents reviewed here means it remains an informed-consent conversation, not a standard-of-care recommendation.

Prescribers should also confirm that patients are not concurrently using MAO inhibitors, serotonin-norepinephrine reuptake inhibitors at high doses, or other dopaminergic agents without pharmacological review, because Semax's dopaminergic activity could produce additive effects in those combinations.